Tapinarof Cream 1% Once Daily for the Treatment of Extensive Atopic Dermatitis in Adolescents and Children: Outcomes from the 4-Week Maximal Usage Trial
Main Article Content
Keywords
atopic dermatitis, eczema, maximal usage pharmacokinetics, tapinarof cream 1% once daily, AhR agonist
References
1. Dermavant Sciences. VTAMA (tapinarof) cream, 1%: US prescribing information. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215272s000lbl.pdf.Accessed August 2023.
2. Peppers J, et al. J Am Acad Dermatol. 2019;80:89–98.
3. Paller A, et al. J Am Acad Dermatol. 2021;84:632–638.
4. Lebwohl M, et al. N Engl J Med. 2021;385:2219–2229. 5. Strober B, et al. J Am Acad Dermatol. 2022;87:800–806.
6. Bissonnette R, et al. Clin Pharmacol Drug Dev. 2018;7:524–531.
7. Jett JE, et al. Am J Clin Dermatol. 2022;23:83–91.
8. Hanifin JM and Rajka G. Acta Dermato-Venereologica. 1980;60: Suppl 92, 44–47.
2. Peppers J, et al. J Am Acad Dermatol. 2019;80:89–98.
3. Paller A, et al. J Am Acad Dermatol. 2021;84:632–638.
4. Lebwohl M, et al. N Engl J Med. 2021;385:2219–2229. 5. Strober B, et al. J Am Acad Dermatol. 2022;87:800–806.
6. Bissonnette R, et al. Clin Pharmacol Drug Dev. 2018;7:524–531.
7. Jett JE, et al. Am J Clin Dermatol. 2022;23:83–91.
8. Hanifin JM and Rajka G. Acta Dermato-Venereologica. 1980;60: Suppl 92, 44–47.